Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Understanding and targeting pathogenic IgG4 responses

Project description

Understanding the mechanisms of IgG4-related autoimmune diseases

Autoimmune diseases (AIDs) are mediated by autoantibodies. Imunoglobulin G4 (IgG4) is a subclass of IgG antibodies and is largely unable to activate the immune system. In 2015, a group of autoimmune diseases was recognised to be caused by predominantIgG4autoantibodies (IgG4-AIDs). Over the decade since that discovery, at least 29 diseases have been classified as IgG4-AIDs. Building on this observation in 2015, the researcher initiated the ERC-funded IGG4-START project to investigate the antigenic and environmental factors that initiate and drive IgG4 autoimmune responses. The project will make use of state-of-the-art technology including human lymphoid organoids, AI-based antigen-antibody modelling and patient-derived monoclonal antibodies.

Objective

The predominant autoantibody (sub)class is an important determinant in the pathophysiology of autoimmune diseases (AID). Autoantibodies can be pro-inflammatory, such as IgG1, causing disease by complement-mediated or immune cell-mediated tissue damage. In 2015 I was the first to describe a second group of AID where IgG4 autoantibodies, which are largely unable to activate the immune system, cause disease. Till date at least 29 different diseases classify as IgG4-predominated AID (IgG4-AID).
Why certain AID are predominated by IgG4 autoantibodies is not known, but this is confirmed to be critical for precipitation, mechanism and treatment of the disease. In fact selective permissive determinants for class switching to IgG4 in general are not known. Recently, I realized that in contrast to IgG1 autoantigens, IgG4 autoantigens are single pass transmembrane proteins which are continuously shed from the cell. I therefore hypothesize that a key element of the aetiology of IgG4-AID is IgG4-AID antigen shedding resulting in chronic, systemic antigen stimulation in the absence of ‘danger’ signals like bacterial antigens, viral antigens or cellular damage. The goal of this project is therefore to unravel the antigenic and environmental cues that initiate and drive IgG4 (autoreactive) responses following this innovative paradigm, and to find strategies to specifically reduce pathogenic IgG4 responses.
I will study this hypothesis using the archetypical IgG4-AID MuSK myasthenia gravis as a model. The combination of state-of-the-art antibody technologies including human lymphoid organoids and AI-based antigen-antibody modelling, with my IgG4 autoimmunity expertise and our set of patient-derived monoclonal antibodies, puts me in an unique position to address the goal of this project. I furthermore aim to provide a first proof of concept for specifically targeting IgG4+ B cells in vitro to pave the way for new therapeutic strategies for IgG4-AID and other IgG4-associated diseases

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

ACADEMISCH ZIEKENHUIS LEIDEN
Net EU contribution
€ 1 493 090,00
Address
ALBINUSDREEF 2
2333 ZA Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 493 090,00

Beneficiaries (1)